Baliashvili Davit, Shadaker Shaun, Furukawa Nathan, Getia Vladimer, Tsereteli Maia, Symum Hasan, Armstrong Paige A, Tohme Rania A, Handanagic Senad
The Task Force for Global Health, Tbilisi, Georgia.
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Lancet Gastroenterol Hepatol. 2025 Sep;10(9):831-841. doi: 10.1016/S2468-1253(25)00124-4. Epub 2025 Jul 10.
Achieving low incidence is one of WHO's key targets for the elimination of hepatitis C virus (HCV) infection. As progress in Georgia's hepatitis C elimination programme moves the country closer to reaching this target, tracking new cases of hepatitis C has become a priority. We aimed to estimate temporal trends in hepatitis C incidence among people who were tested more than once for hepatitis C in Georgia.
We conducted a retrospective cohort study in adults (aged ≥18 years) tested at least twice for antibodies against HCV (anti-HCV), with the first test being non-reactive, in Georgia from Jan 1, 2017, to Dec 31, 2023. Data were extracted from Georgian national hepatitis C screening and treatment databases on Jan 8, 2024. We calculated the incidence of anti-HCV seroconversion and current chronic HCV infections per 100 000 person-years and 95% CIs overall for 2017-23 and by year for 2017-22. For people who seroconverted but did not undergo testing to confirm current infection, we used multiple imputations to impute the status of current chronic HCV infection. To estimate the magnitude of change, we calculated incidence rate ratios (IRRs) with 95% CIs.
Among 1 264 181 adults with repeat anti-HCV testing during the study period, 519 936 (41·1%) were men and 744 245 (58·9%) were women. In total, 18 846 (1·5%) seroconverted to anti-HCV-reactive after a median follow-up time of 1025 days (IQR 503-1553). The overall incidence rate of anti-HCV seroconversion was 514 cases per 100 000 person-years (95% CI 506-521). The overall estimated incidence rate of current chronic HCV infection was 293 cases per 100 000 person-years (288-299). The annual incidence rate of anti-HCV seroconversion was 3·7 times lower in 2022 than in 2017, declining from 1399 cases per 100 000 person-years (1346-1454) to 377 cases per 100 000 person-years (361-394; IRR 0·27 [95% CI 0·25-0·29]). The annual incidence rate of chronic HCV infection was 4·6 times lower in 2022 than in 2017, declining from 935 cases per 100 000 person-years (892-981) to 205 cases per 100 000 person-years (193-217; IRR 0·22 [95% CI 0·20-0·24]).
We found a high but decreasing incidence rate of hepatitis C in Georgia among people tested more than once. The country should scale up preventive interventions to reduce incidence further and reach elimination targets.
None.
For the Georgian translation of the abstract see Supplementary Materials section.
实现低发病率是世界卫生组织消除丙型肝炎病毒(HCV)感染的关键目标之一。随着格鲁吉亚丙型肝炎消除计划取得进展,该国离实现这一目标越来越近,追踪丙型肝炎新病例已成为当务之急。我们旨在估算格鲁吉亚多次接受丙型肝炎检测人群中丙型肝炎发病率的时间趋势。
我们在2017年1月1日至2023年12月31日期间对格鲁吉亚年龄≥18岁且至少接受过两次抗HCV抗体检测(首次检测为阴性)的成年人进行了一项回顾性队列研究。数据于2024年1月8日从格鲁吉亚国家丙型肝炎筛查和治疗数据库中提取。我们计算了2017 - 2023年期间每10万人年抗HCV血清学转换和当前慢性HCV感染的发病率及95%置信区间,并按年份计算了2017 - 2022年的发病率。对于血清学转换但未接受检测以确认当前感染状况的人群,我们采用多重填补法估算当前慢性HCV感染状况。为估算变化幅度,我们计算了发病率比(IRR)及95%置信区间。
在研究期间接受重复抗HCV检测的1264181名成年人中,519936名(41.1%)为男性,744245名(58.9%)为女性。共有18846名(1.5%)在中位随访时间1025天(四分位间距503 - 1553天)后血清学转换为抗HCV阳性。抗HCV血清学转换的总体发病率为每10万人年514例(95%置信区间506 - 521)。当前慢性HCV感染的总体估计发病率为每10万人年293例(288 - 299)。2022年抗HCV血清学转换的年发病率比2017年低3.7倍,从每10万人年1399例(1346 - 1454)降至每10万人年377例(361 - 394;发病率比0.27 [95%置信区间0.25 - 0.29])。慢性HCV感染的年发病率2022年比2017年低4.6倍,从每10万人年935例(892 - 981)降至每10万人年205例(193 - 217;发病率比0.22 [95%置信区间0.20 - 0.24])。
我们发现格鲁吉亚多次接受检测人群中丙型肝炎发病率虽高但呈下降趋势。该国应扩大预防干预措施,以进一步降低发病率并实现消除目标。
无。
摘要的格鲁吉亚语翻译见补充材料部分。